One element of Clinton’s plan is largely symbolic: the proposed shortening of the statutory exclusivity period for biologics from 12 years to 7 years. Such a change wouldn’t have much practical effect because most biologics have at least 12 years of US patent protection when they are launched in the US market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.